Jupiter Neurosciences Inc. (JUNS) Stock Forecast & Analysis

Real-time stock price, financial statements, consensus target price, insider trading, and technical analysis for Jupiter Neurosciences Inc. (JUNS:NASDAQ), powered by AI.

Current Price
$0.15
P/E Ratio
-0.6
Market Cap
5M
Sector
Healthcare
What is the Jupiter Neurosciences Inc. stock price forecast?

Jupiter Neurosciences Inc. is currently trading at $0.15. View real-time AI analysis on Alpha Lenz.

What is Jupiter Neurosciences Inc. insider trading activity?

View the latest insider trading data for Jupiter Neurosciences Inc. on Alpha Lenz.

What is Jupiter Neurosciences Inc.'s P/E ratio?

Jupiter Neurosciences Inc.'s P/E ratio is -0.6.

Jupiter Neurosciences Inc.

NASDAQ · JUNS
$0.15-0.02(-12.37%)Pre-marketNASDAQ regular session 09:30–16:00 ET
Ask about Jupiter Neurosciences Inc.'s future dividend policy...
Alpha Chat Insight

Jupiter Neurosciences Inc. trades at a P/E of -0.6 (undervalued) with modest ROE of -738.8%.

Ask for details

Company Overview

Jupiter Neurosciences Inc. is a biotech company dedicated to advancing innovative treatments in the field of neuroscience. The company focuses on the development of therapies that address central nervous system disorders, which may include debilitating conditions such as Alzheimer's disease, multiple sclerosis, and other neurodegenerative diseases. By leveraging cutting-edge research and development, Jupiter Neurosciences aims to create novel pharmaceutical solutions that can significantly improve the quality of life for patients affected by neurological challenges. The firm's work is particularly impactful within the biotechnology and pharmaceutical industries as it targets a critical area of healthcare with a growing demand for effective treatment options. As a player in the biotech sector, Jupiter Neurosciences often engages in clinical trials and collaborates with other research institutions to push the boundaries of current medical understanding and therapies. Its presence in the market underscores the importance of innovation in addressing complex health issues that have extensive impacts on patients and healthcare systems worldwide.

CEOMr. Christer Rosen
SectorHealthcare
IndustryBiotechnology
Employees4

Company Statistics

FY 2025

Profile

$5.30MMarket Cap
$21.80KRevenue
0.00Shares Out
4Employees

Margins

80.59%Gross
-39359.87%EBITDA
-40873.19%Operating
-39662.77%Pre-Tax
-39662.77%Net

Valuation

-0.61P/E
-2.89P/B
243.08EV/Sales
-0.80EV/EBITDA
-0.98P/FCF

Growth (CAGR)

-54.62%Rev 3Yr
-54.57%Rev 5Yr
N/AOp Inc 3Yr
N/AOp Inc 5Yr
N/ANet Inc 3Yr
N/ANet Inc 5Yr

Returns

-146.94%ROA
-738.83%ROE
-145.82%ROIC

Financial Health

$3.79MCash & Cash Equivalents
$3.61MNet Debt
-403.74%Debt/Equity
N/AInterest Cov

Frequently Asked Questions

Jupiter Neurosciences Inc. (ticker: JUNS) is a company listed on NASDAQ in the Healthcare sector (Biotechnology). It has approximately 4 employees. Market cap is $5M.

The current price is $0.153 with a P/E ratio of -0.61x and P/B of -2.89x.

ROE is -738.83% and operating margin is -40873.19%. Annual revenue is $21,796.

Alpha Lenz
Singapore
Treasurer Pte Ltd | License: 202346277E
9 Straits View Marina One West Tower #05-07 Singapore 018937
contact@treasurer.co.kr
©2026 Treasurer Pte Ltd. All rights reserved.
Jupiter Neurosciences Inc. (JUNS) Stock Forecast 2026 $0.15 — Price, Financials & Analyst Targets | Alpha Lenz